23-25 October 2024

Rockville, MD - USA

Bayes 2024

DAY 1 – 23 October 2024

TIME
SPEAKER
AFFILIATION
08:30 - 09:00
Registration
09:00 - 12:30
J. Kyle Wathen
Cytel
SHORT COURSE Navigating the Complexities of Platform Trials: Design and Simulation
12:30 - 13:30
Lunch
13:30 - 13:40
Welcome and Opening
13:40 - 14:10
James Travis
FDA/CDER
The future of the Bayesian Biostatistics in the regulatory world
14:10 - 14:30
Raviv Pryluk
PhaseV
To Bayes or Not to Bayes:Practical Challenges and Considerations in Supporting the Design of Bayesian Adaptive Trials
14:30 - 14:50
Pantelis Vlachos
Cytel
Simulation-based optimization of adaptive designs using a generalized version of assurance
14:50 - 15:10
Yong Zang
Indiana University
A Bayesian Adaptive Marker-Stratified Design for Phase II Clinical Trials Using Calibrated Spike-and-Slab priors
15:10 - 15:30
Michael Sonksen
Eli Lilly and Company
Considerations on Mixture Priors for Historical Borrowing in Confirmatory Studies
15:30 - 15:55
Coffee break
15:55 - 16:25
Peter F. Thall
MD Anderson Cancer Center
Bayesian Personalized Treatment Selection for Advanced Breast Cancer
16:25 - 16:45
Satrajit Roychoudhury
Pfizer
Prediction of Overall Survival (OS) from Disease Progression Dynamics in Metastatic Cancer Trials
16:45 - 17:05
Danila Azzolina
Ferrara University
Navigating Challenges in Pediatric Trial Conduct: Integrating Bayesian Sequential Design with Semiparametric Elicitation for Handling Primary and Secondary Endpoints
17:05 - 17:25
Roberto Crackel
FDA/CDER
Application of Bayesian borrowing methods in clinical trials for children with type II diabetes mellitus using simulation and case studies
17:25 - 17:45
Wenda Tu
FDA/CDER
My experience with Bayesian pediatric extrapolation as a statistical reviewer

The BAYES Organising Committee is delighted to invite all registered delegates to the social dinner at Kumbia Restaurant

DAY 2 – 24 October 2024

TIME
SPEAKER
AFFILIATION
08:30 - 09:00
Jennifer Kirk
FDA/CBER
Bayesian Statistics and Real-World Evidence: A Successful Example from CBER
09:00 - 09:20
Emma K Mackay
Inka Health Toronto
Bayesian Hierarchical Modelling Approaches to Indirect Treatment Comparisons between Single-arm Basket Trials: An Application to NTRK-fusion Solid Tumours
09:20 - 09:40
Sai Dharmarajan
Sarepta Therapeutics
Enhancing Medical Product Development and Review with Bayesian Quantitative Benefit Risk Methods
09:40 - 10:00
Zhengfan Wang
Genesis Research Group
Bayesian Survival Models for Real-World Evidence: Implementation in Assessing Treatment Duration and Mortality Risk
10:00 - 10:20
Laura Thompson
FDA/CDER
Effective sample size of Bayesian studies
10:20 - 10:45
Coffee break
10:45 - 11:15
Yanxun Xu
Johns Hopkins University
Enhancing Decision Making with Causal Inference and Unmeasured Confounders in a Bayesian Framework
11:15 - 11:35
Ryan Batten
Phastar
Bayesian Parametric G-Formula as a Sensitivity Analysis for Causal Inference
11:35 - 11:55
Oshri Machluf
PhaseV
The Wolf Will Live with the Lamb:Combining Conformal Prediction with Bayesian Approaches to Enhance Heterogeneity Detection in Clinical Trials
11:55 - 12:15
Gene Pennello
FDA/CDRH
Weighted Posterior Odds: An Evidence Summary for Decision Making
12:15 - 12:25 MY TALK
IN 5 MINUTES
Danila Azzolina
Ferrara University
Enhancing Pediatric Clinical Trials: A Shiny App for Bayesian Adaptive Semiparametric Design, Communication and Implementation
Reynaldo Martina
University of Utrecht
The application of a Poisson difference model under the skellam distribution assumption for the analysis of the change in count measurements in a random effects repeated measures model
12:25 - 13:30
Lunch
13:30 - 14:00
Yize Zhao
Yale University
Bayesian Modeling for Brain Connectivity and Its Link to Genetics and Behavior
14:00 - 14:20
Elena Sizikova
FDA/CDRH
Bayesian statistical methods for evaluating interchangeability of clinical samples with non-clinical samples in evaluating measurement procedure and diagnostic test accuracy
14:20 - 14:40
Bill Pikounis
Johnson & Johnson
Comparability with Statistical Rigor in Manufacturing Development
14:40 - 15:00
Will Landau
Eli Lilly and Company
brms.mmrm: an R package for Bayesian MMRMs
15:00 - 15:20
Boaz N. Adler
Cytel
Flexibility in Clinical Trial Design using Software in combination with R Code: Incorporating Bayesian Treatment Resistance Assumptions
15:20 - 15:45
Coffee break
15:45 - 16:15
Ying Yuan
MD Anderson Cancer Center
A Bayesian latent-subgroup phase I/II platform design to co-optimize doses in multiple indications
16:15 - 16:35
Jonathon Vallejo
FDA/CDER
FDA Project Optimus: Current Status and General Regulatory Perspectives
16:35 - 16:55
Ming-Dauh Wang
Bayer Pharmaceuticals
A Comprehensive Bayesian Double-Adjustment Approach to Dynamic Borrowing of External Data
16:55 - 17:15
Saijun Zhao
Indiana University
Precision Generalized PhaseI-II Designs for Personalized Dose Optimization

DAY 3 – 25 October 2024

TIME
SPEAKER
AFFILIATION
08:30 - 09:00
Bhramar Mukherjee
Yale University
High Dimensional Bayesian Mediation Analysis for Understanding Biological Mechanisms
09:00 - 09:20
Fatih Kizilaslan
University of Oslo
A Bayesian Approach to Mixture Cure Models from Low-to High-Dimensional Covariate Settings
09:20 - 09:40
Jacqueline Buros
Generable
Multi-State Models with Multiple Timescales: a Bayesian Approach
09:40 -10:00
Mookyong Son
Unlearn.AI
Bayesian Weighted Prognostic Covariate Adjustment Using Digital Twins
10:00 - 10:10 MY TALK
IN 5 MINUTES
Tingting Hu
FDA/CDRH
Evaluating diagnostic test accuracy in studies with extreme verification bias
Joseph Sartini
Johns Hopkins University
Bayesian Multilevel Functional Principal Components Analysis with Application to Continuous Glucose Monitoring Data
10:10 - 10:35
Coffee break
10:35 - 11:05
Amy Crawford
Berry Consultants
Identifying the Population Responsive to EVT: Bayesian Modeling in the STEP Platform Trial
11:05 -11:25
Mark Rothmann
FDA/CDER
Bayesian Supplemental Analysis Demonstration Project
11:25 -11:45
Shaoming Yin
Takeda
Augmenting clinical trial data with external controls through energy balancing weighted power prior
11:45 -12:05
Reynaldo Martina
University of Utrecht
The analysis of TMS-EEG data in a Bayesian multivariate Copula model for prediction of clinical efficacy
12:05 -12:25
Yun Wang
FDA/CDER
Bayesian hierarchical model for subgroup analysis
12:25 - 12:35
Closing Remarks

SPONSORED BY

Code of Conduct

The Adolphe Quetelet Society is an official region of the International Biometric Society (IBS). As such the society endorses the same objectives and Code of Conduct as its mother organization:

IBS Code of Conduct : The International Biometric Society (IBS) highly values professional and appropriate behavior at all times. This involves scientific and ethical integrity, as well as respectful conduct towards others regardless of gender, gender identity and expression, age, sexual orientation, disability, physical appearances, race, religion (or lack thereof) or beliefs.

Members of the IBS, as well as everyone employed on behalf of IBS or attending events organized by IBS, are expected to endorse this position and they agree to be considerate in speech and actions, to respect others, and to refrain from demeaning, discriminatory, or harassing behavior and speech, at all times.

Copyright © 2024 Bayes-Pharma